Results [General Sta­tis­tics]

posted by randombadger – UK, 2011-05-03 14:03 (5522 d 19:50 ago) – Posting: # 6982
Views: 13,404

Dear all,

Thank you for your responses so far, they have been very supportive. Please see below for results from my analyses:

Model 1
PROC MIXED DATA= cmax ;
   CLASS USUBJID period treat ARMCD ;
   MODEL LOG_PARM = treat period ARMCD  /ddfm=KR; 
   RANDOM USUBJID(ARMCD) /G;
   REPEATED/GRP=treat SUB=usubjid ;
   ESTIMATE "B vs A"  TREAT  -1 1 /cl alpha=0.1;
   LSMEANS treat/ cl alpha=0.1;
RUN;

Estimated G Matrix

                                                Planned
                        Unique Subject          Arm
   Row  Effect          Identifier              Code    Col1     Col2

     1  USUBJID(ARMCD)  XXX XXX-X-XXX-00011001  ABB     0.07056     
     2  USUBJID(ARMCD)  XXX XXX-X-XXX-00011003  ABB             0.07056


(block diagonal, apologies for the lack of formatting)
etc

Intra-Subject
CV A (%)    CV B (%)
 31.98       10.02


Model 2
PROC MIXED DATA= cmax ;
  CLASSES armcd usubjid period treat ;
  MODEL LOG_PARM = armcd period treat / DDFM=KR;
  RANDOM treat/TYPE=FA0(2) SUB=usubjid G;
  REPEATED/GRP=treat SUB=usubjid;
  ESTIMATE 'B vs A' treat -1 1/CL ALPHA=0.1;
  LSMEANS treat/ cl alpha=0.1;
RUN;


Estimated G Matrix
                 Unique Subject
Row    Effect    Identifier            TREAT    Col1     Col2

1    TREAT     XXX XXX-X-XXX-00011001    A     0.1036   0.05780
2    TREAT     XXX XXX-X-XXX-00011001    B     0.05780  0.07110


Intra-Subject
CV A (%)    CV B (%)
 22.88        9.78


As you can see, the differences in CV's are quite large hence my concern on the most appropriate code to apply. Note: the treatments were nowhere near bioequivalent.


Edit: Formatted. You may use BBCodes (see here). [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
147 visitors (0 registered, 147 guests [including 22 identified bots]).
Forum time: 09:54 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5